Human T-cell leukemia virus I tax protein sensitizes p53-mutant cells to DNA damage

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4843-4852

  Mihaylova, Valia T ^a,c   Green, Allison M ^a,c   Khurgel, Moshe ^a   Semmes, Oliver J ^b   Kupfer, Gary M ^a,c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MITOMYCIN C; PROTEIN BAX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; RETINOBLASTOMA PROTEIN; TAX PROTEIN; TRANSCRIPTION FACTOR E2F1; VINBLASTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; BAX PROTEIN, HUMAN; BAX PROTEIN, MOUSE; BBC3 PROTEIN, HUMAN; LUCIFERASE; MITOMYCIN; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PMAIP1 PROTEIN, MOUSE; PROTEIN BCL 2; PUMA PROTEIN, MOUSE; TAX PROTEIN, HUMAN T LYMPHOTROPHIC VIRUS 1; TAX PROTEIN, HUMAN T-LYMPHOTROPHIC VIRUS 1; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIMERIZATION; DNA DAMAGE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; T CELL LEUKEMIA; ULTRAVIOLET RADIATION; ANIMAL; CELL CULTURE; CELL CYCLE; CYTOLOGY; DRUG EFFECT; FIBROBLAST; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE; MUTATION; PHYSIOLOGY; RADIATION EXPOSURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELLS, CULTURED; DIMERIZATION; DNA DAMAGE; ETOPOSIDE; FIBROBLASTS; GENE PRODUCTS, TAX; HUMANS; IMMUNOBLOTTING; LUCIFERASES; MICE; MITOMYCIN; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; ULTRAVIOLET RAYS; VINBLASTINE;

EID: 49649129996     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5070     Document Type: Article

References (50)

1. Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 2004;1:20.
2. Franchini G, Nicot C, Johnson JM. Seizing of T cells by human T-cell leukemia/lymphoma virus type 1. Adv Cancer Res 2003;89:69-132.
3. Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992;66:4570-5.
4. Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005;24:5986-95.
5. Ruley HE. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol 1996:37-56.
6. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN. Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J Biol Chem 2001;276: 200-5.
7. Mahieux R, Pise-Masison CA, Nicot C, Green P, Hall WW, Brady JN. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses 2000;16:1677-81.
8. Mulloy JC, Kislyakova T, Cereseto A, et al. Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J Virol 1998;72: 8852-60.
9. Haoudi A, Semmes OJ. The HTLV-1 tax oncoprotein attenuates DNA damage induced G1 arrest and enhances apoptosis in p53 null cells. Virology 2003;305:229-39.
10. Kao SY, Lemoine FJ, Marriott SJ. p53-independent induction of apoptosis by the HTLV-I tax protein following UV irradiation. Virology 2001;291:292-8.
11. Kato T, Hirai T, Yasui K, Nakazato H, Suzuki H. [Blood levels of mitomycin C in patients given by various routes of administration]. Gan To Kagaku Ryoho 1989;16:2639-44.
12. Kozuch P, Hoff PM, Hess K, et al. Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer 2001;91:815-21.
13. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science (New York, NY) 2002;296: 550-3.
14. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1995;1:9-19.
15. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene 1999;18:7873-82.
16. Chau BN, Wang JY. Coordinated regulation of life and death by RB. Nat Rev Cancer 2003;3:130-8.
17. Muller H, Helin K. The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 2000;1470:M1-12.
18. Moroni F, Meli E, Peruginelli F, et al. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 2001;8:921-32.
19. Yoshida H, Kong YY, Yoshida R, et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998;94:739-50.
20. Saavedra HI, Wu L, de Bruin A, et al. Specificity of E2F1, E2F2, and E2F3 in mediating phenotypes induced by loss of Rb. Cell Growth Differ 2002;13:215-25.
21. Leone G, Sears R, Huang E, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 2001;8:105-13.
22. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002;4:859-64.
23. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004;279:8627-34.
24. Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL. Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett 2006;580:5905-9.
25. Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 1999;4:771-81.
26. Holmberg C, Helin K, Sehested M, Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 1998;17:143-55.
27. Stanelle J, Putzer BM. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 2006;12:177-85.
28. Rogoff HA, Kowalik TF. Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle 2004;3:845-6.
29. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 2004;3:1071-9.
30. Li J, Li H, Tsai MD. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity. Biochemistry 2003;42:6921-8.
31. Vendel AC, McBryant SJ, Lumb KJ. KIX-mediated assembly of the CBP-CREB-HTLV-1 tax coactivator-activator complex. Biochemistry 2003;42:12481-7.
32. Xie L, Yamamoto B, Haoudi A, Semmes OJ, Green PL. PDZ binding motif of HTLV-1 Tax promotes virus-mediated T-cell proliferation in vitro and persistence in vivo. Blood 2006;107:1980-8.
33. Majone F, Semmes OJ, Jeang KT. Induction of micronuclei by HTLV-I Tax: a cellular assay for function. Virology 1993;193:456-9.
34. Majone F, Jeang KT. Clastogenic effect of the human T-cell leukemia virus type I Tax oncoprotein correlates with unstabilized DNA breaks. J Biol Chem 2000;275: 32906-10.
35. +) cells: modulation of p21cip1/waf1 and p27kip1 expression. J Virol 2005;79:14069-78.
36. Chowdhury IH, Farhadi A, Wang XF, Robb ML, Birx DL, Kim JH. Human T-cell leukemia virus type 1 Tax activates cyclin-dependent kinase inhibitor p21/Waf1/Cip1 expression through a p53-independent mechanism: inhibition of cdk2. Int J Cancer 2003; 107:603-11.
37. Kehn K, Fuente Cde L, Strouss K, et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene 2005;24:525-40.
38. Suzuki S, Singhirunnusorn P, Mori A, et al. Constitutive activation of TAK1 by HTLV-1 tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-κB. J Biol Chem 2007;282:25177-81.
39. Jin DY, Teramoto H, Giam CZ, Chun RF, Gutkind JS, Jeang KT. A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor α. J Biol Chem 1997;272:25816-23.
40. Mori N. High levels of the DNA-binding activity of E2F in adult T-cell leukemia and human T-cell leukemia virus type I-infected cells: possible enhancement of DNA-binding of E2F by the human T-cell leukemia virus I transactivating protein, Tax. Eur J Haematol 1997;58: 114-20.
41. Iwanaga R, Ohtani K, Hayashi T, Nakamura M. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene 2001;20:2055-67.
42. Haller K, Wu Y, Derow E, Schmitt I, Jeang KT, Grassmann R. Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 2002;22:3327-38.
43. 1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein. J Virol 1998;72:633-40.
44. 1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J Virol 1997;71:3451-7.
45. Ruesch MN, Laimins LA. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol 1997;71:5570-8.
46. Kao SY, Lemoine FJ, Marriott SJ. Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway. J Biol Chem 2000;275:35926-31.
47. Pise-Masison CA, Mahieux R, Jiang H, et al. Inactivation of p53by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation. Mol Cell Biol 2000;20:3377-86.
48. Van PL, Yim KW, Jin DY, Dapolito G, Kurimasa A, Jeang KT. Genetic evidence of a role for ATM in functional interaction between human T-cell leukemia virus type 1 Tax and p53. J Virol 2001;75:396-407.
49. Pommier Y, Weinstein JN, Aladjem MI, Kohn KW. Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin Cancer Res 2006;12:2657-61.
50. Ding HF, Fisher DE. Mechanisms of p53-mediated apoptosis. Crit Rev Oncog 1998;9:83-98.